GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OBI Pharma Inc (ROCO:4174) » Definitions » EV-to-FCF

OBI Pharma (ROCO:4174) EV-to-FCF : -6.26 (As of Jun. 23, 2024)


View and export this data going back to 2015. Start your Free Trial

What is OBI Pharma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, OBI Pharma's Enterprise Value is NT$12,114.01 Mil. OBI Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was NT$-1,934.48 Mil. Therefore, OBI Pharma's EV-to-FCF for today is -6.26.

The historical rank and industry rank for OBI Pharma's EV-to-FCF or its related term are showing as below:

ROCO:4174' s EV-to-FCF Range Over the Past 10 Years
Min: -147.61   Med: -16.8   Max: -6.25
Current: -6.26

During the past 13 years, the highest EV-to-FCF of OBI Pharma was -6.25. The lowest was -147.61. And the median was -16.80.

ROCO:4174's EV-to-FCF is ranked worse than
100% of 402 companies
in the Biotechnology industry
Industry Median: 5.935 vs ROCO:4174: -6.26

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-23), OBI Pharma's stock price is NT$61.00. OBI Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was NT$-5.260. Therefore, OBI Pharma's PE Ratio for today is At Loss.


OBI Pharma EV-to-FCF Historical Data

The historical data trend for OBI Pharma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OBI Pharma EV-to-FCF Chart

OBI Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -17.29 -13.80 -16.40 -6.66 -8.39

OBI Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.70 -11.27 -9.22 -8.39 -7.00

Competitive Comparison of OBI Pharma's EV-to-FCF

For the Biotechnology subindustry, OBI Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OBI Pharma's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OBI Pharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where OBI Pharma's EV-to-FCF falls into.



OBI Pharma EV-to-FCF Calculation

OBI Pharma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=12114.006/-1934.482
=-6.26

OBI Pharma's current Enterprise Value is NT$12,114.01 Mil.
OBI Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-1,934.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OBI Pharma  (ROCO:4174) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

OBI Pharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=61.00/-5.260
=At Loss

OBI Pharma's share price for today is NT$61.00.
OBI Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-5.260.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


OBI Pharma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of OBI Pharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


OBI Pharma (ROCO:4174) Business Description

Traded in Other Exchanges
N/A
Address
No. 3, Park Street, Room. 1907, 19th Floor, Nangang District, Taipei, TWN, 115
OBI Pharma Inc is part of the healthcare sector. The company and its subsidiaries are engaged in new drug research. Its focus is on the unmet medical need in challenging diseases throughout the world, such as cancer. OBI strives to improve health and the quality of life through cost-effective therapeutics. The Group has four reportable segments, which are the anti-cancer new drug segment, bispecific monoclonal antibody new drug segment, botulinum toxin new drug segment, and CDMO segment.

OBI Pharma (ROCO:4174) Headlines

No Headlines